Nxera Pharma Co., Ltd.
SOLTF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $579,167 | $85,720,073 | $79,670,628 | $87,078,107 |
| - Cash | $192,396 | $32,997,000 | $34,465,000 | $36,203,000 |
| + Debt | $426,826 | $64,723,000 | $66,264,000 | $67,900,000 |
| Enterprise Value | $813,597 | $117,446,073 | $111,469,628 | $118,775,107 |
| Revenue | $45,657 | $8,450,000 | $6,644,000 | $6,852,000 |
| % Growth | -99.5% | 27.2% | -3% | – |
| Gross Profit | $27,588 | $6,592,000 | $5,029,000 | $4,725,000 |
| % Margin | 60.4% | 78% | 75.7% | 69% |
| EBITDA | -$12,209 | $532,000 | -$1,111,000 | -$2,775,000 |
| % Margin | -26.7% | 6.3% | -16.7% | -40.5% |
| Net Income | -$11,303 | -$2,377,000 | -$760,000 | -$1,335,000 |
| % Margin | -24.8% | -28.1% | -11.4% | -19.5% |
| EPS Diluted | -0.12 | -26.35 | -8.45 | -14.86 |
| % Growth | 99.5% | -211.8% | 43.1% | – |
| Operating Cash Flow | -$20,118 | -$180,000 | $613,000 | -$10,970,000 |
| Capital Expenditures | -$690 | -$90,000 | -$109,000 | -$153,000 |
| Free Cash Flow | -$20,807 | -$270,000 | $504,000 | -$11,123,000 |